Form 4: CONMED Director Sells 2,000 Shares Under 10b5-1 Plan
Insider Transaction Report
CONMED Corporation Director Charles Farkas sold 2,000 shares of common stock for approximately $107,050 on September 12, 2025, under a pre-arranged trading plan.
Summary
- Charles Farkas, a Director of CONMED Corporation (CNMD), sold 2,000 shares of the company's common stock.
- The transactions occurred on September 12, 2025.
- The shares were sold in two separate transactions: 1,103 shares at $53.535 per share and 897 shares at $53.512 per share.
- The total value of the shares sold was approximately $107,050.
- Following these sales, Charles Farkas directly beneficially owns 14,859 shares of CONMED common stock.
- The transactions were made pursuant to a Rule 10b5-1(c) trading plan, indicating they were pre-scheduled.
Sentiment
Score: 5
Explanation: A neutral score as the sale was pre-arranged under a 10b5-1 plan, indicating it was not a discretionary sale based on new information, and the amount is not exceptionally large relative to the director's remaining holdings or the company's market cap.
Future Outlook
NA
Industry Context
This is a routine insider transaction and does not provide specific industry context or relate to broader industry trends.
Related Party Transactions
- Charles Farkas, a Director of CONMED Corporation, sold shares of the company's common stock.
Stakeholder Impact
- Shareholders: The sale by a director, even if pre-arranged, could be perceived differently by investors, though a 10b5-1 plan mitigates concerns about opportunistic selling.
Key Dates
| Date | Description |
|---|---|
| 2025-05-20 | Date Charles M Farkas executed the Limited Power of Attorney. |
| 2025-09-12 | Date of common stock transactions by Charles Farkas. |
| 2025-09-15 | Date the Form 4 was signed by Power of Attorney. |
Recommendation
holdThe filing reports a routine, pre-scheduled sale of a relatively small number of shares by a director under a 10b5-1 plan. This type of transaction is generally not indicative of new material information or a change in the company's fundamental outlook. It does not provide a basis for a 'buy' or 'sell' recommendation, thus a 'hold' is appropriate as it doesn't alter the investment thesis.
Keywords
CONMED Corp, CNMD, Insider Sale, Form 4, Director Transaction, Charles Farkas, Stock Sale, 10b5-1 Plan, Equity Disposal
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.